Rozerem Related Published Studies
Well-designed clinical trials related to Rozerem (Ramelteon)
Effects of ramelteon 8 mg on objective sleep latency in adults with chronic insomnia on nights 1 and 2: pooled analysis. [2009.05]
Safety and subjective sleep effects of ramelteon administration in adults and older adults with chronic primary insomnia: a 1-year, open-label study. [2009.04]
Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. [2009.03.01]
Ramelteon for the treatment of insomnia in menopausal women. [2009.03]
Effects of long-term exposure to ramelteon, a melatonin receptor agonist, on endocrine function in adults with chronic insomnia. [2009.03]
Effect of ramelteon on middle-of-the-night balance in older adults with chronic insomnia. [2009.02.15]
Ramelteon for insomnia symptoms in a community sample of adults with generalized anxiety disorder: an open label study. [2009.02.15]
Circadian phase-shifting effects of repeated ramelteon administration in healthy adults. [2008.10.15]
Ramelteon 8 mg/d versus placebo in patients with chronic insomnia: post hoc analysis of a 5-week trial using 50% or greater reduction in latency to persistent sleep as a measure of treatment effect. [2008.07]
Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty. [2007.09]
Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. [2007.08.15]
Ramelteon for the treatment of insomnia. [2006.10]
Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. [2006.06]
Disposition Kinetics and Tolerance of Escalating Single Doses of Ramelteon, a High-Affinity MT1 and MT2 Melatonin Receptor Agonist Indicated for Treatment of Insomnia. [2006.02]
An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. [2006.01]
Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. [2005.03.01]
Other research related to Rozerem (Ramelteon)
The effects of ramelteon in a first-night model of transient insomnia. [2009.01]
Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. [2009.01]
Effects of long-term exposure to ramelteon, a melatonin receptor agonist, on endocrine function in adults with chronic insomnia. [2008.12.17]
Selective activation of melatonin receptors with ramelteon improves liver function and hepatic perfusion after hemorrhagic shock in rat. [2008.10]
Ramelteon: a novel approach in the treatment of insomnia. [2008.09]
The effects of ramelteon in a first-night model of transient insomnia. [2008.08.06]
Effect of Ramelteon, a selective MT(1)/MT (2)-receptor agonist, on respiration during sleep in mild to moderate COPD. [2008.08]
Efficacy and clinical safety of ramelteon: an evidence-based review. [2008.08]
Ramelteon: A Novel Approach in the Treatment of Insomnia (CE) (September). [2008.07.23]
Ramelteon: a melatonin receptor agonist for the treatment of insomnia. [2008.01]
Sorafenib: in hepatocellular carcinoma. [2008]
Effect of Ramelteon, a selective MT(1)/MT (2)-receptor agonist, on respiration during sleep in mild to moderate COPD. [2007.12.01]
Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea. [2007.09]
A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia. [2007.05]
Drug Insight: the use of melatonergic agonists for the treatment of insomnia-focus on ramelteon. [2007.04]
Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. [2007.04]
Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea. [2007.02.10]
Ramelteon for insomnia in two youths with autistic disorder. [2006.10]
Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. [2006.10]
Searching for new options for treating insomnia: are melatonin and ramelteon beneficial? [2006.07]
Ramelteon: a novel treatment for the treatment of insomnia. [2006.07]
Ramelteon: profile of a new sleep-promoting medication. [2006.04]
Ramelteon. [2005]
Other possibly related research studies
Pharmacologic management of insomnia: past, present, and future. [2006.12]
Practical considerations of new drugs: new choices for old problems. [2006.04]
Melatonin and sleep in aging population. [2005.12]
TAK-375 Takeda. [2005.01]
Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. [2004.11]
Therapeutic options for sleep-maintenance and sleep-onset insomnia. [2007.01]
Gateways to clinical trials. [2006.07]
Treating insomnia: Current and investigational pharmacological approaches. [2006.12]
Management of chronic insomnia in elderly persons. [2006.06]
Use of sleep-promoting medications in nursing home residents : risks versus benefits. [2006]
Potential therapeutic use of melatonin in migraine and other headache disorders. [2006.04]
Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. [2005]
Gateways to clinical trials. [2005.10]
Gateways to clinical trials. [2004.12]
Gateways to clinical trials. [2004.11]
Gateways to clinical trials. [2004.07]
Gateways to clinical trials. [2003.11]
Use of non-benzodiazepine hypnotics in the elderly: are all agents the same? [2007]
Greater incidence of depression with hypnotic use than with placebo. [2007.08.21]
Treatment options for insomnia. [2007.08.15]
New perspectives for the treatment of disorders of sleep and arousal. [2007.07]
Pharmacotherapy for insomnia. [2008.02]
Gateways to clinical trials. [2007.10]
Role of the melatonin system in the control of sleep: therapeutic implications. [2007]
Melatonergic drugs in clinical practice. [2008]
[New hypnotics: perspectives from sleep physiology] [2007.07]
[Melatonin. Physiology and clinical applications] [2007.07]
Will insomnia treatments produce overall cost savings to commercial managed-care plans? A predictive analysis in the United States. [2007.06]
Jet lag: therapeutic use of melatonin and possible application of melatonin analogs. [2008.01]
Possibility that certain hypnotics might cause cancer in skin. [2008.09]
Hypnotic use for insomnia management in chronic obstructive pulmonary disease. [2009.01]
|
